The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
Walter Reed National Military Medical Center
Study ID
NCT06275373
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Teprotumumab Injection [Tepezza] — DRUG
    IGF1 monoclonal antibody

Study Details

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Key Dates

Start date
May 12, 2021
Status verified
Feb 2024
Primary completion
May 12, 2026
Completion
Dec 12, 2027

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Ophthalmological Clinical Activity Score (CAS) scoring [ Time Frame: 6-12 months post treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Walter Reed National Military Medical CenterBethesdaMaryland20889
Thanh D Hoang, DO
[email protected]
301-295-5165
Iris E Morris, PhD
[email protected]
3013194599

Find similar trials in Bethesda, MD

By research site
Walter Reed National Military Medical Center· Bethesda, MD

Related Studies